Should rheumatologists be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at ACR Convergence 2023 suggests that this should be an important conversation with our female lupus patients.
Dr. John Cush RheumNow
2 years 8 months ago
Polands disease study (sarcoidosis 78.6K; #AOSD 3294; systemic sclerosis 35.5K) betw 2009-2018. Avg hospitalization was 5.39 days sarcoidosis, 6.22 days scleroderma, & 7.44 days for Still’s (latter decr 11.7 to 5.8, betw 2008-2014) https://t.co/OcNzt7IKC5 https://t.co/uPcbOyizQN
Guidelines (ACR/EULAR/GRAPPA) for the management of psoriatic arthritis (PsA) recommend the early referral of patients with the suspected condition for early assessment and treatment. There remains a diagnostic delay of 1-2 years in PsA and ideally treatment should be commenced within 1 year of symptom onset.
How early is early in PsA and is there a window of opportunity for treatment in PsA to ensure optimal outcomes?
Dr. John Cush RheumNow
2 years 8 months ago
Naltrexone was NOT superior to placebo in a blinded RCT of 99 Fibromyalgia pts. Pain decreased –1·3 points w/ NAL vs –0·9 in PBO (p=0·27). D/C were similar (8% vs 6%). NAL may improve improve memory problems in FM pts. https://t.co/5i98Jr4u84 https://t.co/SkEbLaMfvI
Arthritis & Rheumatology has published a new study that suggests knee or hip osteoarthritis patients who are overweight or obese may have less premature death if slow to moderate rate of weight loss results from anti-obesity medications.
Dr. John Cush RheumNow
2 years 8 months ago
Post-Menopausal Osteoporosis Review and Recommendations
A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations.
https://t.co/GJzR7q82si https://t.co/DOA4G1fQlV
Dr. John Cush RheumNow
2 years 8 months ago
Proof-of-concept, open label study of 30 #GCA pts (mean age 74 yrs) Rx w/ 12 mos of weekly tocilizumab & 8wks of prednisone. At wk 52 77% were in sustained pred-free remission & 23% relapsed at mean 16 wks (none w/ visual loss) https://t.co/Tbwhqs91Mf https://t.co/kZWkp5g87m
Dr. John Cush RheumNow
2 years 8 months ago
No difference in SIE/hospitalized infxn in #RA Tx w/ ABAtacept, csDMARDs or other b/tsDMARDs - from 5 data sets (2 biologic registries, NDB, 2 claims databases). IRs per 1000PYs: ABA (16-56), csDMARDs (19-46), b/tsDMARDs (18-40). No diff in OI https://t.co/WaPUNHJb76 https://t.co/uXWe7LDLpJ
Most rheumatologists know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though: the details are difficult, it is overwhelming for the patient, and the conversations are hard.
Dr. John Cush RheumNow
2 years 8 months ago
Difficult-to-treat (D2T) axSpA seen in 88/311 axSpA pts. D2T axSpA= failure of ≥2 b/tsDMARDs (Very D2T-axSpA: same in <2yrs). D2T had signif more periph arthritis (35 vs 21%), higher BASDAI (64 v 59) & more FM. Very D2T had more CRP, IBD, no FM https://t.co/DnxxypAEqo https://t.co/B5TxvDoYy4
Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA.

